| Date Filed | Type | Description |
| 10/13/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/10/2023 |
SC 13G
| TANG CAPITAL PARTNERS LP reports a 8.6% stake in Bionomics Limited |
| 07/13/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 11% stake in ASLAN Pharmaceuticals Limited |
| 06/06/2023 |
SC 13G
| TANG CAPITAL PARTNERS LP reports a 6.1% stake in AVROBIO, Inc. |
| 06/01/2023 |
SC 13D
| TANG CAPITAL PARTNERS LP reports a 14.1% stake in Rain Oncology Inc. |
| 05/05/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 05/05/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/17/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/31/2023 |
SC 13G
| TANG CAPITAL PARTNERS LP reports a 10% stake in Quince Therapeutics, Inc. |
| 03/28/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/17/2023 |
SC 13D/A
| TANG CAPITAL PARTNERS LP reports a 10.2% stake in Jounce Therapeutics, Inc. |
| 03/17/2023 |
SC 13G
| TANG CAPITAL PARTNERS LP reports a 10% stake in Bellerophon Therapeutics, Inc. |
| 03/14/2023 |
SC 13D
| TANG CAPITAL PARTNERS LP reports a 10.2% stake in Jounce Therapeutics, Inc. |
| 03/13/2023 |
SC 13G
| TANG CAPITAL PARTNERS LP reports a 5.3% stake in Adicet Bio, Inc. |
| 03/06/2023 |
SC 13G
| TANG CAPITAL PARTNERS LP reports a 9.7% stake in Jounce Therapeutics, Inc. |
| 02/24/2023 |
SC 13G
| TANG CAPITAL PARTNERS LP reports a 5.8% stake in Elevation Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 0% stake in Corvus Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 5.3% stake in CytomX Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 3.2% stake in Heron Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 0% stake in Inspirato Incorporated |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 9.4% stake in KalVista Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 10% stake in Metacrine, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 9.9% stake in Pyxis Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 10% stake in Reviva Pharmaceuticals Holdings, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 7.5% stake in Tarsus Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 7.1% stake in TCR2 Therapeutics Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 2% stake in Albireo Pharma, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 7.8% stake in ASLAN Pharmaceuticals Limited |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 8.6% stake in BioAtla, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 5.6% stake in bluebird bio, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 7.4% stake in Tonix Pharmaceuticals Holding Corp. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 7.1% stake in Aligos Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| TANG CAPITAL PARTNERS LP reports a 5.5% stake in Altimmune, Inc. |
|